

Cover Story
FreeGuest Editorial
By Jhanelle E. Gray, Karen Reckamp, Mary Redman, Konstantin H. Dragnev, Ellen V. Sigal, Shakun Malik, Meg Mooney, James H. Doroshow and Charles D. Blanke
S2302 Pragmatica-Lung is a federally-funded, streamlined clinical trial examining a new combination of agents in patients with advanced non-small cell lung cancer (NSCLC). Like most studies, it is focused on improving outcomes for patients with cancer—but it is also poised to simplify and transform the entire clinical trials model as we know it.
Cancer History ProjectFree
By Alexandria Carolan and Katie Goldberg
Trending Stories
- GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise - U.S. News & World Report expands evaluation of outcomes in cancer subspecialties
- Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies? - Cancer Research Institute announces 2025 recipients of cancer immunotherapy awards
- Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home